CSL Behring is ready to begin operations in its newly expanded manufacturing facility in Kankakee, Illinois following approval of the facility by the US Food and Drug Administration. The expansion increased plasma processing and albumin production capacity. 

The new facility will use the same technology as CSL Behring's manufacturing center of excellence in Bern, Switzerland. This is an important step towards a common fractionation process throughout CSL Behring's global manufacturing network. The expansion is necessary due to the growing worldwide demand for CSL Behring's immunoglobulins and albumin.

The expansion in Kankakee is part of CSL Behring's multi-site expansion plan, which includes the expansion of its manufacturing facilities in Broadmeadows, Australia; Bern, Switzerland; and Marburg, Germany. Increasing Kankakee's ability to fractionate plasma and produce albumin and intermediate paste is an important step for the company’s global operations. The intermediate paste produced in Kankakee is sent to CSL Behring's other manufacturing facilities where it is used to make therapies for the treatment of immune deficiencies, bleeding and other medical disorders. Albumin is a plasma expander that quickly makes up for blood loss in accident victims, and that is also used to treat burn patients.

Source: CSL Behring